Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxigene has started patient dosing in its phase Ib trial in advanced solid tumors which combines its lead vascular disrupting agent, CA4P, with antiangiogenic agent Avastin.
Subscribe to our email newsletter
In recent published research, the combination of a Vascular Disrupting Agent (VDA) with an antiangiogenic agent was described as offering a powerful and highly targeted regimen for suppressing tumor growth.
“We believe that the combination of CA4P and Avastin has the potential to bring significant benefit to patients. This patient enrollment also highlights our renewed focus on executing our programs rapidly and on schedule,” stated Dr Richard Chin, president and CEO of Oxigene.
Oxigene believes that this dose escalation trial is the first step toward fully elucidating the efficacy and safety profiles of combining VDAs and antiangiogenic agents in patients.
Oxigene is an emerging pharmaceutical company developing small-molecule therapeutics to treat cancer and eye diseases. The company’s major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.